摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-bromo-5,6-dichloro-1-(2,3,5-tri-O-acetyl-β-L-ribofuranosyl)benzimidazole | 176161-18-5

中文名称
——
中文别名
——
英文名称
2-bromo-5,6-dichloro-1-(2,3,5-tri-O-acetyl-β-L-ribofuranosyl)benzimidazole
英文别名
2-Bromo-5,6-dichloro-1-(2,3,5-tri-O-acetyl-beta-L-ribofuranosyl)-1H-benzimidazole;2-bromo-5,6-dichloro-1-(2,3,5-tri-O-acetyl-β-L-ribofuranosyl)-1H-benzimidazole;2-Bromo-5,6-dichloro-1-(2,3,5-tri-O-acetyl--L-ribofuranosyl)-1H-benzimidazole;[(2S,3S,4S,5S)-3,4-diacetyloxy-5-(2-bromo-5,6-dichlorobenzimidazol-1-yl)oxolan-2-yl]methyl acetate
2-bromo-5,6-dichloro-1-(2,3,5-tri-O-acetyl-β-L-ribofuranosyl)benzimidazole化学式
CAS
176161-18-5
化学式
C18H17BrCl2N2O7
mdl
——
分子量
524.152
InChiKey
YOHBOWGRGQAKAT-QAETUUGQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    611.6±65.0 °C(Predicted)
  • 密度:
    1.75±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    30
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    106
  • 氢给体数:
    0
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis and Evaluation of a Series of 2′-Deoxy Analogues of The Antiviral Agent 5,6-Dichloro-2-Isopropylamino-1-(β-L-Ribofuranosyl)-1H-Benzimidazole (1263W94)
    作者:Joseph H. Chan、Stanley D. Chamberlain、Karen K. Biron、Michelle G. Davis、Robert J. Harvey、Dean W. Selleseth、Ronna E. Dornsife、Ernest H. Dark、Lloyd W. Frick、Leroy B. Townsend、John C. Drach、George W. Koszalka
    DOI:10.1080/15257770008032999
    日期:2000.1
    and branched alkylamino groups were needed for potent activity against HCMV. Three analogues 3a, 3b and 3d were as potent as 1263W94. Further evaluation of two analogues, 3a and 3b, suggested that these 2'-deoxy analogues may act via a novel mechanism of action similar to that of 1263W94. These 2'-deoxy analogues generally lacked cytotoxicity in vitro. Pharmacokinetic parameters in mice and protein
    合成了抗病毒剂5,6-二-2-异丙基基-1-(β-L-核呋喃糖基)-1H-苯并咪唑(1263W94)的一系列2'-脱氧类似物,并评估了其对人巨细胞病毒(HCMV)的活性并具有细胞毒性。苯并咪唑部分中的2-取代基对应于1263W94系列中使用的那些。通常,如在1263W94系列中发现的那样,环状和支链烷基基基团需要有效的抗HCMV活性。三个类似物3a,3b和3d与1263W94一样有效。对两个类似物3a和3b的进一步评估表明,这些2'-脱氧类似物可以通过类似于1263W94的新颖作用机制起作用。这些2'-脱氧类似物通常在体外缺乏细胞毒性。小鼠的药代动力学参数和3a的蛋白质结合特性与1263W94非常相似。但是,3a的口服生物利用度仅为1263W94观察到的一半。
  • Process for preparing substituted benzimidazole compounds
    申请人:——
    公开号:US20030191127A1
    公开(公告)日:2003-10-09
    The invention relates to new methods of preparing substituted benzimidazole compounds, such as 2-bromo-5,6-dichlorobenzimidazole, which are useful in the preparation of compounds having antiviral activity.
    这项发明涉及一种制备取代苯并咪唑化合物的新方法,例如2--5,6-二氯苯并咪唑,这些化合物在具有抗病毒活性的化合物的制备中非常有用。
  • [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSES THERAPEUTIQUES
    申请人:THE WELLCOME FOUNDATION LIMITED
    公开号:WO1996001833A1
    公开(公告)日:1996-01-25
    (EN) The present invention relates to benzimidazole derivatives and their use in medical therapy particularly for the treatment or prophylaxis of virus infections such as those caused by herpes viruses. The invention also relates to the preparation of the benzimidazole derivatives and pharmaceutical formulations containing them.(FR) L'invention concerne des dérivés de benzimidazole ainsi que leur utilisation en thérapie médicale, notamment dans le traitement ou la prophylaxie d'infections virales telles que celles provoquées par les herpèsvirus. L'invention concerne également la préparation des dérivés de benzimidazole ainsi que des formulations pharmaceutiques les contenant.
    (中) 本发明涉及苯并咪唑生物及其在医学治疗中的应用,特别是用于治疗或预防由疱疹病毒引起的病毒感染。本发明还涉及苯并咪唑生物的制备以及含有它们的制药配方。
  • Therapeutic compounds
    申请人:——
    公开号:US20010003744A1
    公开(公告)日:2001-06-14
    The present invention relates to benzimidazole derivatives and their use in medical therapy particularly for the treatment or prophylaxis of virus infections such as those caused by herpes viruses. The invention also relates to the preparation of the benzimidazole derivatives and pharmaceutical formulations containing them.
    本发明涉及苯并咪唑生物及其在医疗治疗中的应用,特别是用于治疗或预防病毒感染,例如由疱疹病毒引起的感染。本发明还涉及苯并咪唑生物的制备以及含有它们的制药配方。
  • PROCESS FOR PREPARING SUBSTITUTED BENZIMIDAZOLE COMPOUNDS
    申请人:Freeman Stephen
    公开号:US20080188668A1
    公开(公告)日:2008-08-07
    The invention relates to new methods of preparing substituted benzimidazole compounds, such as 2-bromo-5,6-dichlorobenzimidazole, which are useful in the preparation of compounds having antiviral activity.
    本发明涉及一种制备取代苯并咪唑化合物的新方法,例如2--5,6-二氯苯并咪唑,该方法对于制备具有抗病毒活性的化合物非常有用。
查看更多

同类化合物

直链-苯并腺苷二磷酸酯 [(2R,3R,4R,5R)-2-(5,6-二氯苯并咪唑-1-基)-4-羟基-5-(羟基甲基)四氢呋喃-3-基]磷酸二氢酯 BENZIMIDAVIR苯并咪唑核苷 8-氨基-3-beta-D-呋喃核糖基咪唑并[4,5-g]喹唑啉 5,6-二甲基-1-(5-O-膦酰-alpha-D-呋喃核糖基)-1H-苯并咪唑 5,6-二氯-1-β-D-呋喃核糖基苯并咪唑 2-氯-5,6-二甲基-1-beta-D-呋喃核糖基苯并咪唑 2,5-哌嗪二酮,3-甲基-6-(2-甲基丙基)-,反-(9CI) 1,3-二去氮杂腺苷 (2S,3R,4S,5R)-2-(5,6-二甲基苯并咪唑-1-基)-5-(羟基甲基)四氢呋喃-3,4-二醇 2-amino-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-1H-benzimidazole 2,5,6-trichloro-1-(2-O-acetyl-3,5-di-O-benzoyl-β-L-xylofuranosyl)benzimidazole 1-(2',3',5'-tri-O-acetyl-α-D-lyxofuranosyl)-2,5,6-trichlorobenzimidazole Acetic acid (2R,3R,4R,5S)-4-acetoxy-5-acetoxymethyl-2-(2-bromo-5,6-dichloro-benzoimidazol-1-yl)-tetrahydro-furan-3-yl ester α-Ribazol-3'(2')-phosphorsaeureester 1-(2,3,5-tri-O-acetyl-α-L-lyxofuranosyl)-2,5,6-trichlorobenzimidazole 2'-Benzoyl-1-β-D-ribofuranosylbenzimidazol (1Ξ)-1-(5,6-dimethyl-benzimidazol-1-yl)-1,4-anhydro-L-arabitol 1-(6-acetylamino-4-bromo-imidazo[4,5-c]pyridin-1-yl)-tri-O-benzoyl-α-D-1-deoxy-ribofuranose 2-azido-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-1H-benzimidazole 3'-Benzoyl-1-β-D-ribofuranosylbenzimidazol tri-O-acetyl-1-(8-methylsulfanyl-imidazo[4,5-g]quinazolin-1-yl)-β-D-1-deoxy-ribofuranose 3-aminopropyl-2'-(α-ribazolyl)-diphosphate 1-(6-acetylamino-4-bromo-imidazo[4,5-c]pyridin-1-yl)-tri-O-benzoyl-β-D-1-deoxy-ribofuranose 1-(6-amino-4-methylsulfanyl-imidazo[4,5-c]pyridin-1-yl)-β-D-1-deoxy-ribofuranose 2-iodo-5,6-dichloro-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)benzimidazole Formamidoribosid 2-bromo-5,6-dichloro-1-(2,3,5-tri-O-acetyl-β-L-ribofuranosyl)benzimidazole Formamidoribosid 5,6-dichloro-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)benzimidazole-2-thione 1-(tri-O-benzoyl-β-D-ribofuranosyl)-1,3-dihydro-benzoimidazole-2-thione 5,6-dichloro-1-β-D-ribofuranosylbenzimidazolyl-(2'->5')-5,6-dichloro-1-β-D-ribofuranosylbenzimidazolyl-(2'->5')-5,6-dichloro-1-β-D-ribofuranosylbenzimidazole bis(triethylammonium) salt 5,6-dichloro-1-β-D-ribofuranosylbenzimidazolyl-(2'->5')-5,6-dichloro-1-β-D-ribofuranosylbenzimidazole triethylammonium salt tri-O-benzoyl-1-(2-methylsulfanyl-benzoimidazol-1-yl)-β-D-1-deoxy-ribofuranose 2-Allylthio-1-(β-D-ribofuranosyl)benzimidazol 1-benzoimidazol-1-yl-tri-O-benzoyl-α-D-1-deoxy-ribofuranose Acetic acid (2R,3R,4R,5R)-4-acetoxy-5-acetoxymethyl-2-(4,6-dichloro-2-thioxo-2,3-dihydro-benzoimidazol-1-yl)-tetrahydro-furan-3-yl ester 2-Chloro-6-bromo-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)benzimidazole 6-amino-1-(tri-O-benzoyl-β-D-ribofuranosyl)-1,5-dihydro-imidazo[4,5-c]pyridine-4-thione Bis-5',5'- 1-(6-amino-4-bromo-imidazo[4,5-c]pyridin-1-yl)-tri-O-benzoyl-β-D-1-deoxy-ribofuranose (2R,3R,4R,5R)-2-(acetoxymethyl)-5-(5,6-dimethoxy-1H-benzo[d]imidazol-1-yl)tetrahydrofuran-3,4-diyl diacetate 2-azido-4,6-dichloro-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)benzimidazole 2-bromo-4,6-dichloro-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)benzimidazole 2,4,6-trichloro-1-(β-D-ribofuranosyl)benzimidazole 1-(2,3,5-Tri-O-acetyl-α-D-ribofuranosyl)-5,6-dimethyl-benzimidazol od. α-Ribazol-triacetat 2,4,6-trichloro-1-(2,3,5-tri-O-acetyl-α-D-ribofuranosyl)benzimidazole 2-bromo-6-trifluoromethyl-1-(5-deoxy-beta-D-ribofuranosyl)-1H-benzimidazole